Granted Patent B1

US 12,653,834 · App. 19/272,505 · Granted Jun 16, 2026

Inventors: Gregory J. Flesher (Irvine, CA); Gail Cawkwell (Irvine, CA)

Assignee: Ambros Therapeutics, Inc.

A61K31/663A61K9/0019

Abstract

Claims (10)

1 . A method of selectively treating CRPS Type 1 comprising:

(A) identifying a patient that has been diagnosed as having CRPS Type 1 as a patient that is likely to have reduction in pain intensity of 50% or more in response to aminobisphosphonate treatment and selecting that patient to receive treatment by confirming that the patient has:

(i) edema in the affected limb and at least two of the following:

1) redness in the affected limb relative to the contralateral limb,

2) ≥1° C. increase in temperature on the affected limb relative to the contralateral limb, and

3) moderate to severe edema, and

(ii) increased uptake of a radiolabeled agent in the affected limb relative to the contralateral limb in a triple phase bone scan (TPBS);

wherein the patient is experiencing a pain intensity greater than 4 on the 11-point numeric rating scale (NRS); and

(B) administering to the selected patient a 400 mg total dose of neridronate, wherein the selected patient achieves a reduction in pain intensity of 50% or more.

2 . The method of claim 1 , wherein the patient has 1) redness in the affected limb relative to the contralateral limb, 2) ≥1° C. increase in temperature on the affected limb relative to the contralateral limb, and 3) moderate to severe edema.

Assignments (1)

Continuity (1)

References Cited (370)